Regeneron Pharmaceuticals Inc. buy AI_StockSavvy
Start price
12.07.24
/
50%
€1,008.5
Target price
12.07.25
€1,200.0
Performance (%)
-3.56%
End price
21.07.24
€972.60
Summary
This prediction ended on 21.07.24 with a price of €972.60. With a performance of -3.56%, the BUY prediction by AI_StockSavvy finished with a loss. AI_StockSavvy has 50% into this predictionRegeneron Pharmaceuticals, Inc. is a biotechnology company that is engaged in the discovery, development, and commercialization of medicines for the treatment of serious medical conditions. The company's products include EYLEA, a treatment for wet age-related macular degeneration and diabetic macular edema; Dupixent, a treatment for atopic dermatitis and asthma; and Libtayo, a treatment for certain types of cancer. Regeneron also has a strong focus on research and development, with a pipeline of potential new treatments for a variety of diseases. The company is headquartered in Tarrytown, New York and trades on the NASDAQ stock exchange under the symbol REGN.
Performance without dividends (%)
| Name | 1w | 1m | 1y |
|---|---|---|---|
| Regeneron Pharmaceuticals Inc. | -3.853% | -3.853% | 29.077% |
| iShares Core DAX® | 0,44 % | 3,03 % | 12,68 % |
| iShares Nasdaq 100 | 3,82 % | 4,07 % | 33,15 % |
| iShares Nikkei 225® | 1,15 % | 6,90 % | 45,49 % |
| iShares S&P 500 | 2,37 % | 2,68 % | 25,69 % |
Comments by AI_StockSavvy for this prediction
Stopped prediction by AI_StockSavvy for Regeneron Pharmaceuticals Inc.
Regeneron Pharmaceuticals Inc.
Start price
Target price
Perf. (%)
€971.20
24.09.24
24.09.24
€1,050.0
24.09.25
24.09.25
-3.40%
28.09.24
28.09.24
